三甲基硅烷化重氮甲烷 溶液

• 产品号: 92738
• CAS号: 18107-18-1
• 分子式: C4H10N2Si
• 分子量: 114.2211

产品别名

• 标题: (Trimethylsilyl)diazomethane solution
• IUPAC标准名: (diazomethyl)trimethylsilane
• IUPAC传统名: trimethylsilyldiazomethane
• 别名: (三甲硅烷)重氮甲烷; (Diazomethyl)trimethylsilane

产品登记号

• Beilstein号: 1902903
• MDL号: MFCD00053946
• CAS号: 18107-18-1
• PubChem SID: 24889702

产品性质

• 浓度: ~2 M in hexane
• 级别: technical
• 线性分子式: (CH3)3SiCHN2
• 闪点: -26 °C
• 闪点: -14.8 °F
• GHS警示词: Danger
• GHS危险声明: H225-H304-H315-H330-H336-H350-H361f-H370-H411
• 欧盟危险性物质标志: 易燃性(Flammable) (F)
• 欧盟危险性物质标志: 剧毒(Highly toxic) (T+)
• 欧盟危险性物质标志: 环境危害性(Nature polluting) (N)
• 个人保护装置: Eyeshields, Faceshields, full-face respirator (US), Gloves, multi-purpose combination respirator cartridge (US), type ABEK (EN14387) respirator filter
• GHS警示性声明: P201-P210-P260-P273-P281-P284
• RID/ADR: UN 1992 3/PG 2
• 危险公开号: 45-11-26-38-39/26-51/53-62-65-67
• 安全公开号: 53-28-36/37-45-61-62
• 联合国危险货物等级: 3
• 联合国危险货物编号: 1992
• 联合国危险货物包装类别(PG): 2
• 德国WGK号: 3

产品详细信息

详细说明 (English)

Application
Reactant for preparation of:
• Macrolactam analogs of the natural product macrolide (-)-A26771B with improved metabolic stability and antibacterial activity1
• Aigialomycin D analogues as protein kinase inhibitors for cancer treatment2
• Unnatural α-amino acid derivatives containing gem-bisphosphonates via Michael addition reaction3
• Capped 4-methylumbelliferyl hyaluronan disaccharides and tetrasaccharides as potential hyaluronidase substrates4
• Stictamides A-C as matrix metallopeptidase 12 (MMP12) inhibitors with antitumor invasion activity5
• Endothelin converting enzyme (ECE) Inhibitors WS 75624A and WS 75624B via a cross-metathesis approach6
• Ent-kaurene derivatives as anti-inflammatory agents7
• Desmosdumotin C analogs as potent antitumor agents acting via activation of spindle assembly checkpoint8
• Imidazolo[2,1-b]benzothiazole derivatives as potential p53 inhibitors9

详细说明 (简体中文)

Application
Reactant for preparation of:
• Macrolactam analogs of the natural product macrolide (-)-A26771B with improved metabolic stability and antibacterial activity1
• Aigialomycin D analogues as protein kinase inhibitors for cancer treatment2
• Unnatural α-amino acid derivatives containing gem-bisphosphonates via Michael addition reaction3
• Capped 4-methylumbelliferyl hyaluronan disaccharides and tetrasaccharides as potential hyaluronidase substrates4
• Stictamides A-C as matrix metallopeptidase 12 (MMP12) inhibitors with antitumor invasion activity5
• Endothelin converting enzyme (ECE) Inhibitors WS 75624A and WS 75624B via a cross-metathesis approach6
• Ent-kaurene derivatives as anti-inflammatory agents7
• Desmosdumotin C analogs as potent antitumor agents acting via activation of spindle assembly checkpoint8
• Imidazolo[2,1-b]benzothiazole derivatives as potential p53 inhibitors9